A New Approach to ADHD Treatment
A first-in-class medication introduces a new mechanism of action for treating attention-deficit/hyperactivity disorder (ADHD).
In July 2026, the U.S. Food and Drug Administration (FDA) approved centanafadine (Simtriyo), a new once-daily medication for ADHD in adults and children aged 6 years and older who weigh at least 44 pounds (20 kg).
This approval represents an important development in ADHD treatment, introducing a medication that acts on three neurotransmitter systems rather than primarily targeting one or two.
What Makes Centanafadine Different?
Centanafadine is the first FDA-approved norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD.
These three neurotransmitters play important roles in attention, motivation, emotional regulation, and cognitive functioning.
Norepinephrine contributes to alertness, attention, and executive functioning.
Dopamine is involved in motivation, reward processing, and attention regulation.
Serotonin influences mood, emotional regulation, and other neurological processes.
By inhibiting the reuptake of all three neurotransmitters, centanafadine offers a different pharmacological approach from existing ADHD medications.
Although its mechanism is distinct, centanafadine is classified as a central nervous system (CNS) stimulant, not a non-stimulant medication.
What Does the Research Show?
FDA approval was supported by four pivotal Phase 3 clinical trials involving adults, adolescents, and children with ADHD.
Across these studies, centanafadine demonstrated statistically significant improvements in ADHD symptoms compared with placebo. Improvements were observed as early as the first week of treatment in some study populations.
These findings are encouraging, particularly because ADHD treatment is highly individualized. However, additional research and real-world clinical experience will help clarify how centanafadine compares with established medications over time.
What Should Patients Know?
As with any psychiatric medication, potential benefits must be considered alongside safety and tolerability.
Commonly reported adverse effects in adults included headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea.
Centanafadine also carries important safety warnings, including risks related to misuse, abuse, and addiction, as well as suicidal thoughts and behaviors in pediatric patients. Other precautions include potential cardiovascular and psychiatric effects.
At the time of this article, commercial availability remains pending completion of the federal controlled-substance scheduling process.
Expanding Options for Individualized ADHD Care
The approval of centanafadine highlights the continued evolution of ADHD treatment and the growing recognition that individuals may respond differently to medications based on their symptoms, medical history, coexisting conditions, and treatment goals.
While a new mechanism of action does not necessarily mean a medication will be more effective or better tolerated than existing treatments, expanding available options is a meaningful step forward.
At Encompass Health & Psychiatry, we believe effective mental healthcare begins with individualized, evidence-based treatment decisions and consideration of the whole person.
Staying informed about emerging research and therapeutic developments is one way we support that philosophy.
Sources & Further Reading
U.S. Food and Drug Administration. (2026). Simtriyo (centanafadine) prescribing information.
Otsuka Pharmaceutical. (2026, July 24). FDA approval announcement for Simtriyo.
Centanafadine (Simtriyo): A first-in-class triple reuptake inhibitor approved for ADHD.
This article is provided for educational purposes and does not constitute individualized medical advice. Medication decisions should be made in consultation with a qualified healthcare professional.
Comments